Victoza Articles
New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients
18 March 2013
Positive new Ph III data on Novo Nordisk's Victoza
28 November 2012
Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"
23 November 2012
Highlights of American Diabetes Association meeting
11 June 2012
Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal
23 April 2012
Victoza sales boost Novo Nordisk
3 February 2012
GlaxoSmithKline’s albiglutide fails to show superiority over Novo Nordisk’s Victoza
18 November 2011
EU OKs two new indications for Novo Nordisk’s Levemir
3 November 2011
AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza
10 October 2011
Obesity drug market set to grow to $2.6 billion by 2020, says DR report
27 September 2011
Approval of diabetes drugs from AstraZeneca/B-MS and Novo Nordisk supported by EU’s CHMP; Faslodex cleared in Japan
26 September 2011
Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS
13 September 2011
Most surveyed physicians in Europe expect to increase Rxing of GLP-1 analogues and DPP-IV inhibitors
18 August 2011
Novo Nordisk first-half 2011 sales and profit leap
4 August 2011
Type 2 diabetes agents - DPP-IV inhibitors - will be main beneficiaries of pioglitazone problems
1 August 2011
China approves Novo Nordisk diabetes drug Victoza
16 March 2011
Novo Nordisk subpoenaed in the USA over marketing
16 February 2011
Novo Nordisk’s first nine months 2010 sales grew 17%, beating forecasts, driven by Victoza, NovoRapid and Levemir; NICE backs Victoza
27 October 2010
Impact of Avandia restrictions could benefit Januvia, Byetta and Victoza, US physician survey reveals
7 October 2010
Type 2 diabetes drug market to nearly double to $36 billion in 2019, boosted by news drugs; research shows many patients not taking their insulin
23 September 2010
Positive new data on diabetes drugs from Novo Nordisk, AstraZeneca/B-MS and Sanofi-Aventis presented at EASD meeting
21 September 2010
Roche/Ipsen’s diabetes drug taspoglutide stumbles on safety grounds, meaning delay in approval
21 June 2010
UK’s NICE backs Novo Nordisk’s Victoza in revised preliminary recommendation; firm discontinues some products in UK
15 June 2010
Novo Nordisk reports new data demonstrating superior efficacy of Victoza over Januvia in type 2 diabetes
23 April 2010
US FDA exec questions safety of Lilly and Amylin’s Byetta, saying it may pose cancer risk
12 April 2010
Showing 1-42 of 42 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
